London, UK-headquartered cancer drug developer Antisoma says its tumour-vascular disrupting agent, ASA404, will enter a second Phase III trial this year.
The ATTRACT-2 trial, conducted by Antisoma's partner, Novartis, will be a randomized, double-blind, placebo-controlled, multicentre Phase III trial including approximately 900 patients receiving their second treatment for stage IIIb/IV non-small cell lung cancer. Patients will be randomly assigned to receive either ASA404 1800 mg/m2 plus docetaxel or a placebo plus docetaxel. The primary endpoint will be overall survival.
Glyn Edwards, Antisoma's chief executive, said the firm was "very pleased to see Novartis expanding the ASA404 development programme to explore the drug's potential to benefit second-line as well as first-line lung cancer patients. Since there is a clear need for improved treatment options in the second-line setting, we believe this represents a substantial additional opportunity for ASA404."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze